CASI (CASI Pharmaceuticals) EV-to-Revenue : 2.10 (As of Dec. 16, 2024)

View and export this data going back to 1996. Start your Free Trial

What is CASI Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CASI Pharmaceuticals's enterprise value is $46.39 Mil. CASI Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $22.06 Mil. Therefore, CASI Pharmaceuticals's EV-to-Revenue for today is 2.10.

The historical rank and industry rank for CASI Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

CASI' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.12 Med: 93.17 Max: 13268.97
Current: 2.1

During the past 13 years, the highest EV-to-Revenue of CASI Pharmaceuticals was 13268.97. The lowest was -0.12. And the median was 93.17.

CASI's EV-to-Revenue is ranked better than
77.64% of 1042 companies
in the Biotechnology industry
Industry Median: 7.54 vs CASI: 2.10

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-12-16), CASI Pharmaceuticals's stock price is $3.11. CASI Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $1.57. Therefore, CASI Pharmaceuticals's PS Ratio for today is 1.98.

CASI Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for CASI Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals EV-to-Revenue Chart

CASI Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

65.01

21.43

2.95

-0.08

2.55

CASI Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-Revenue	Get a 7-Day Free Trial															0.48	2.55	1.63	3.69	4.24

Competitive Comparison of CASI Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, CASI Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CASI Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's EV-to-Revenue falls into.

CASI Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

CASI Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	46.393	/	22.055
	=	2.10

CASI Pharmaceuticals's current Enterprise Value is $46.39 Mil.
CASI Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.06 Mil.

CASI Pharmaceuticals (NAS:CASI) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

CASI Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	3.11	/	1.573
	=	1.98

CASI Pharmaceuticals's share price for today is $3.11.
CASI Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.57.

CASI Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CASI Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (NAS:CASI) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 81, Jianguo Road, Room 1701-1703, Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025

Website

https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Executives

James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Wei-wu He	director, 10 percent owner, officer: Chairman and CEO	ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Weihao Xu	officer: Chief Financial Officer	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Larry Zhang	officer: President	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Shrotriya Rajesh C Md	director	157 TECHNOLOGY DRIVE, IRVINE CA 92618
Salisbury Franklin Cary Jr	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Yue Alexander Wu	director	C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Wealth Strategy Holding Ltd	10 percent owner	LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK
Alexander A Zukiwski	officer: Chief Medical Officer	200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
George Chi	officer: Chief Financial Officer	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Dapeng Li	10 percent owner	BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008
Idg-accel China Growth Fund Iii L.p.	10 percent owner	UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000
Spectrum Pharmaceuticals Inc	10 percent owner	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Sparkle Byte Ltd	10 percent owner	P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000
Ken Ren	director, officer: CEO and Director	3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065